Should ADAURA Trial Results Change Practice in NSCLC? Should ADAURA Trial Results Change Practice in NSCLC?
Dr Mark Kris says yes and explains why he thinks 3-year treatment with osimertinib should become the new standard of care for patients with EGFR mutation – positive NSCLC.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news